Retirement Systems of Alabama Reduces Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Retirement Systems of Alabama lessened its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 16.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 333,287 shares of the company’s stock after selling 67,962 shares during the quarter. Retirement Systems of Alabama’s holdings in Teva Pharmaceutical Industries were worth $6,732,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. AQR Capital Management LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 24.6% in the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after acquiring an additional 4,732 shares during the last quarter. Focus Partners Wealth lifted its position in Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after purchasing an additional 1,739 shares during the period. Signaturefd LLC boosted its holdings in Teva Pharmaceutical Industries by 45.0% in the second quarter. Signaturefd LLC now owns 9,814 shares of the company’s stock valued at $164,000 after purchasing an additional 3,046 shares during the last quarter. Sound Income Strategies LLC boosted its holdings in Teva Pharmaceutical Industries by 3,715.8% in the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after purchasing an additional 2,824 shares during the last quarter. Finally, PFG Investments LLC grew its position in Teva Pharmaceutical Industries by 12.5% during the 2nd quarter. PFG Investments LLC now owns 18,148 shares of the company’s stock worth $304,000 after purchasing an additional 2,013 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 12,300 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the completion of the transaction, the chief accounting officer owned 5,650 shares of the company’s stock, valued at $170,630. This represents a 68.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the sale, the insider directly owned 52,828 shares in the company, valued at $1,517,748.44. This represents a 80.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 622,060 shares of company stock valued at $17,076,965. 0.49% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Trading Down 0.5%

Shares of NYSE:TEVA opened at $33.04 on Friday. The business’s 50 day moving average price is $30.29 and its 200-day moving average price is $23.03. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $33.44. The firm has a market capitalization of $37.90 billion, a price-to-earnings ratio of 27.54, a price-to-earnings-growth ratio of 1.89 and a beta of 0.66. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 48.20%. The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the prior year, the business posted $0.71 earnings per share. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 results materially beat expectations — EPS $0.96 vs. $0.65 consensus and revenue $4.71B vs. $4.36B; management highlighted branded-drug strength (notably Austedo) and a Sanofi milestone that lifted the quarter. TEVA’s Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
• Positive Sentiment: Fourth-quarter profit/revenue rise story notes the milestone payment that kicked off a late‑stage IBD study and helped drive results — supports the case for durable branded-product growth. Teva Pharmaceutical profit, revenue rise in fourth quarter
• Positive Sentiment: Analysts raised targets: Truist bumped its target to $38 (buy) and Scotiabank to $40 (sector outperform), signaling dealer confidence in upside from the beat and pipeline progress. Benzinga TickerReport — Scotiabank target raise
• Positive Sentiment: Company highlights 3rd consecutive year of growth (2025 revenues $17.3B) and positions its pipeline as value‑creating, which supports a longer‑term growth narrative beyond near‑term guidance. GlobeNewswire — Teva delivers 3 consecutive years of growth
• Neutral Sentiment: Company released the earnings slide deck and hosted an earnings call — useful for investors wanting details on segment trends, pipeline timelines and margin assumptions. MarketBeat — Earnings materials
• Neutral Sentiment: Seeking Alpha published the Q4 earnings call transcript and the results presentation for investors who want full management commentary and Q&A. SA — Earnings call transcript SA — Presentation
• Neutral Sentiment: PR/awareness activity (Will Forte campaign about Huntington’s disease) may raise public awareness but is unlikely to move near‑term fundamentals materially. Yahoo Finance — Will Forte Teams Up with Teva
• Negative Sentiment: FY‑2026 guidance is cautious on revenue: EPS guidance of 2.57–2.77 is roughly in line with consensus, but the revenue range of $16.4–16.8B sits below the ~$17.0B street estimate — investors may view this as a near‑term headwind despite the quarter’s beat.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. The Goldman Sachs Group upped their target price on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Truist Financial upped their price objective on Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday. Barclays assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Tuesday, December 9th. They set an “overweight” rating and a $35.00 price objective on the stock. Scotiabank boosted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday. Finally, Bank of America raised their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Buy” and an average target price of $35.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.